Skip to content

Helix Diagnostics

Learn more about our genomics tests

Ongoing access to real-time, point-of-care, clinically indicated genomics insights to improve your ability to take a personalized genomics approach to every patient's care.

Helix Pharmacogenomics (PGx) Clopidogrel Test

Test Description

Useful for providing a genetic evaluation to determine optimal prescription based on risk of side effects and drug efficacy for clopidogrel. This test can identify a patient’s metabolizer status for CYP2C19, which can aid in appropriate prescription and dosing to reduce risk of side effects and treatment failure with clopidogrel.

This test utilizes next-generation sequencing to determine star alleles and metabolizer status for CYP2C19 and is used to determine drug considerations for Clopidogrel. See Method Description for additional details.

Important Test Information

Turnaround time: 10-14 days

Preferred specimen: 3mL Lavender top (BD Vacutainer EDTA, T944)

Shipping instructions: Specimens to arrive at Helix within 96 hours of collection at room temperature.

Clopidogrel is an antiplatelet medication prescribed to patients at increased risk of blood clots, including those who have a history of cardiac events or major cardiac intervention. Clopidogrel prevents the collection of platelets and formation of blood clots in the blood vessels.

In order to successfully prevent platelet collection and clot formation, clopidogrel is turned into its active metabolite by CYP2C19. An individual’s CYP2C19 genotype can impact the concentration of active metabolite in the plasma, which may increase risk for treatment failure and adverse cardiac and cerebrovascular events such as heart attack and stroke. Knowing a patient’s CYP2C19 genotype can help determine if an alternate drug should be prescribed to reduce this risk.

All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.